Search company, investor...
Abaxis company logo

Abaxis

abaxis.com

Founded Year

1989

Stage

Acq - P2P | Acquired

Total Raised

$7.37M

Valuation

$0000 

About Abaxis

Abaxis supplies point of care blood analyzers to the medical market and the veterinarian market. Abaxis provides technology, tools and services that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. Abaxis is headquartered in northern California, USA, and conducts operations around the world.

Headquarters Location

3240 Whipple Road

Union City, California, 94587,

United States

800-822-2947

Missing: Abaxis's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Abaxis's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Abaxis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Abaxis is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

8,606 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

H

Health IT

7,901 items

Abaxis Patents

Abaxis has filed 45 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Analytical chemistry
  • Immunologic tests
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/20/2019

2/22/2022

Clusters of differentiation, Immunology, Immune system, Immunologic tests, Bacterial diseases

Grant

Application Date

3/20/2019

Grant Date

2/22/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Immunologic tests, Bacterial diseases

Status

Grant

Latest Abaxis News

Veterinary Hematology Analyzers Market is expected to grow from USD 850 million in 2022 to USD 1515.9 million by 2030 : GreyViews

Jan 27, 2023

Major Players IDEXX, VetScan, Abaxis, Clindiag Systems, Boule Medical, Woodley Equipment, Sysmex, Siemens Healthineers, Drew Scientific, Diatron MI, HemoCue, Heska, Mindray Medical International, HORIBA Medical, Urit Medical, Qreserve, Rayto Life and Analytical Sciences. among other Segmentation Analysis The tabletop analyzers  segment is expected to be the fastest-growing segment in 2022. The product type segment is divided into tabletop analyzers and point-of-care analyzers. The tabletop analyzers are further divided into fully automatic and semiautomatic analyzers. The point-of-care analyzers are further divided into cartridge-based and direct sample-based analyzers. The tabletop analyzers  segment will witness the highest growth rate during the forecast period. Tabletop analyzers offer a thorough, comprehensive analysis. They are easy to use. Because there are so few sample requirements, it is quite compatible in a volatile environment. Low-maintenance instruments called tabletop analyzers are often employed in veterinary medicine. The growing animal population and the spread of diseases have increased the market demand for tabletop analyzers. Both fully automatic and semiautomatic analyzers dominate the market for tabletop analyzers. They offer a comprehensive analysis with superb precision. The 3-part WBC differential  segment is expected to be the fastest-growing segment in 2022. The analysis parameter segment is divide into 2-part WBC differential, 3-part WBC differential, 5-part WBC differential and others. The 3-part WBC differential  segment is expected to witness the highest growth rate during the forecast period. A 3-part WBC differential can be used to calculate the blood's concentration of monocytes, neutrophils, and lymphocytes. These analyzers are common in medical or veterinary hospitals, clinics, and diagnostic labs. They are popular in the veterinary field because they offer sufficient diagnostic data to pinpoint the ailment or condition plaguing the animal or pet. It works well and quickly to identify viral and bacterial infections. Due to the high prevalence of zoonotic diseases, primarily bacterial or viral, the market utilisation of 3-part WBC differential analyzers is growing. The veterinary hospitals and clinics segment is expected to be the fastest-growing segment in 2022. The end-user segment is divided into research institutes, veterinary hospitals and clinics, veterinary diagnostic centers, point-of-care testing, inhouse-testing, and others. The veterinary hospitals and clinics segment is expected to witness the highest growth rate during the forecast period. Since hospitals and clinics are the primary healthcare providers worldwide and are regarded in high regard by the general public, individuals usually turn to them first for their pets and domesticated animals. Veterinarian hospitals and clinics have all the supplies needed to provide the finest care for animals, including the medications, equipment, and other necessities. The increase in pet adoption has also led to the opening and operation of veterinary hospitals and clinics by both public and private actors to offer veterinary healthcare services to anyone in need. The opening of walk-in clinics with trained employees on hand to assist the patients coming in will hasten the growth of this industry. Regional Analysis            The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the veterinary hematology analyzers include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North America region witnessed a major share. There are a lot of meat eaters in the area. The regional cuisine of the North American market consumes a lot of meat. Commercial animal breeding is required to supply top-notch animal health, meet the demands of the sizable meat-eating populace, and safeguard consumer interests. The North American market has expanded as a result of stringent governmental rules and several organisations dedicated to the health and wellbeing of animals. The COVID-19 pandemic demonstrates the need for increased zoonotic disease incidence monitoring in order to prevent catastrophic destruction. Country Analysis Germany Germany's veterinary hematology analyzers market size was valued at USD 79.05 million in 2022 and is expected to reach USD 145.23 million by 2030, at a CAGR of 7.9% from 2023 to 2030. The demand for veterinary haematology analyzers is anticipated to rise as awareness of animal diseases increases, animal healthcare facilities are used more frequently, and the companion insurance healthcare programme implemented in Germany to enhance the effectiveness of the country's animal healthcare systems. China China’s veterinary hematology analyzers market size was valued at USD 55.25 million in 2022 and is expected to reach USD 100.01 million by 2030, at a CAGR of 7.7% from 2023 to 2030. The increasing incidence of meat consumption, growing worry over zoonotic illnesses, and the rapidly growing animal healthcare sector are all aspects that will help the market in the nation. The increasing number of cattle in the nation and the high incidence of pet adoption are also significant factors propelling the veterinary haematology analyzer market. India India's veterinary hematology analyzers market size was valued at USD 42.5 million in 2022 and is expected to reach USD 76.36 million by 2030, at a CAGR of 7.6% from 2023 to 2030. Modern veterinary haematology analyzers are in high demand due to the country's rapid increase in the prevalence of lifestyle diseases in dogs and cats, including as obesity and diabetes, which is driving the market's expansion. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of the veterinary hematology analyzers market is mainly driven by the increase in incidences of zoonotic diseases. Buy Now Full Report @ https://greyviews.com/checkout/469/single_user_license Contact Us Browse Related Reports: Veterinary Hematology Analyzers Market Size By Product Type (Table Top Analyzers (Fully Automatic Analyzers and Semiautomatic Analyzers) and Point of Care Analyzers (Cartridge-Based Analyzers and Direct Sample Based Analyzers), By Analysis Parameter (2-Part WBC Differential, 3-Part WBC Differential, 5-Part WBC Differential, and Others), By End-User (Research institutes, Veterinary hospitals and clinics, Veterinary diagnostic centers, point-of-care testing, inhouse-testing, and others), Regions, Segmentation, and Projection till 2030 Structural Heart Devices Market Size By Indication (Atrial Septal Defects, Aortic Valvular Disease, Pulmonary Valvular Disease, Patent Foramen Ovale, Ventricular Septal Defects, Mitral Valvular Disease, Patent Ductus Arteriosus, and Others), By Product Type (Heart Valve Devices, Annuloplasty Rings, Occluders and Delivery Systems, Transcatheter Mitral Valve Repair, and Others), By Procedure(Repair and Replacements), Regions, Segmentation, and Projection till 2030            Shoulder Arthroplasty Market Size By Indication (Arthritis, Fracture/Dislocation, Rotator Cuff Tear Arthropathy, Hill Sachs Defect, and Others), By Device (Shoulder Arthroplasty Resurfacing Implants, Shoulder Arthroplasty Trauma Devices, and Shoulder Arthroplasty Platform Systems), By Procedure (Partial Shoulder Arthroplasty, Total Shoulder Arthroplasty, Reverse Shoulder Arthroplasty, and Revision Shoulder Arthroplasty), Regions, Segmentation, and Projection till 2030

Abaxis Frequently Asked Questions (FAQ)

  • When was Abaxis founded?

    Abaxis was founded in 1989.

  • Where is Abaxis's headquarters?

    Abaxis's headquarters is located at 3240 Whipple Road, Union City.

  • What is Abaxis's latest funding round?

    Abaxis's latest funding round is Acq - P2P.

  • How much did Abaxis raise?

    Abaxis raised a total of $7.37M.

  • Who are the investors of Abaxis?

    Investors of Abaxis include Zoetis, Horizon Offshore, Mayfair Capital Investment Management and MedVenture Associates.

  • Who are Abaxis's competitors?

    Competitors of Abaxis include Truvian Sciences, Theranos, BionX Medical Technologies, MSDx, Drew Scientific and 16 more.

Compare Abaxis to Competitors

M
Mercator MedSystems

Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.

P
Pulse Metric

Pulse Metric designs, manufactures and markets products and services that transform a simple blood pressure reading into a powerful functional profile of the patients cardiovascular system, including cardiac output, vessel compliance, vascular resistance and left ventricular contractility. Within a minute of uploading a DynaPulse blood pressure waveform to the DynaPulse Analysis Center website, 17 hemodynamic parameters are calculated, displayed and trended, providing clinicians with numeric values profiling the hearts pumping performance, blood vessel elasticity and vascular resistance, against normative ranges.The company believes the simplicity of its methodology and the significance of the information provided to the physician will improve quality of care while reducing costs. Pulse Metric has been granted nine patents in support of its proprietary technology.

L
LifePoint

Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.

C
Cardiodynamics International Corporation

CardioDynamics was incorporated in 1993 and is committed to fundamentally changing drug management with ICG. The Company's primary product, the BioZ, uses proprietary Impedance Cardiography (ICG) technology to noninvasively assess a patient's hemodynamics, data which typically has been unavailable in the physician's office and available on a limited basis in the hospital only through a time-consuming, costly, and potentially dangerous invasive procedure called Pulmonary Artery Catheterization (PAC), or the Swan Ganz Catheter. Since the BioZ's ICG monitoring is noninvasive, it can be performed in outpatient areas such as physician offices, which have never before had access to hemodynamic information in treating heart failure, high blood pressure, pacemaker, and dialysis patients. In physician offices, BioZ monitoring can decrease long term costs of hypertension management through the use of appropriate drug therapies. The reduction of blood pressure results in a decrease of more costly cardiovascular conditions including heart failure, strokes, and heart attacks. In hospitals, BioZ monitoring on surgical or intensive care patients can decrease costs through the elimination of procedure risk, reduction of hospital stay, and minimization of hospital expenditures and personnel. BioZ monitoring can also provide valuable hemodynamic information in hospital areas where previously it has not been available, such as emergency departments, critical care, step-down units, and dialysis. In this new era of cost containment, healthcare payors and providers are demanding greater efficiency and cost-effectiveness without diminishing the quality of care. The BioZ's ICG monitoring systems provide a solution to meet this growing demand.

A
Aksys

Aksys has developed an automated personal hemodialysis system for patient-performed hemodialysis in alternative care settings such as the patient's home.

F
Forth Photonics

Forth Photonics is a medical device company that designs, develops, manufactures and markets imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. Forth Photonics aims to help medical practitioners to improve patient care by incorporating advanced biophotonics and optical molecular imaging technologies to assist in early detection, diagnosis and monitoring.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.